Pathological and therapeutic implications of eosinophil-derived semaphorin 4D in eosinophilic chronic rhinosinusitis

J Allergy Clin Immunol. 2020 Mar;145(3):843-854.e4. doi: 10.1016/j.jaci.2019.12.893. Epub 2020 Feb 5.


Background: Eosinophilic chronic rhinosinusitis (ECRS) is a subtype of chronic rhinosinusitis. Clinical markers for ECRS disease activity and treatment strategies have not been sufficiently established. Although semaphorins are originally identified as neuronal guidance factors, it is becoming clear that they play key roles in immune regulation and inflammatory diseases.

Objective: We sought to investigate the pathological functions and therapeutic potential of semaphorin 4D (SEMA4D) in ECRS.

Methods: Serum soluble SEMA4D levels in patients with paranasal sinus diseases were measured by ELISA. The expression of SEMA4D in blood cells and nasal polyp tissues was assessed by flow cytometry and immunohistochemistry, respectively. Generation of soluble SEMA4D was evaluated in matrix metalloproteinase-treated eosinophils. Endothelial cells were stimulated with recombinant SEMA4D, followed by eosinophil transendothelial migration assays. Allergic chronic rhinosinusitis was induced in mice using Aspergillus protease with ovalbumin. The efficacy of treatment with anti-SEMA4D antibody was evaluated histologically and by nasal lavage fluid analysis.

Results: Serum soluble SEMA4D levels were elevated in patients with ECRS and positively correlated with disease severity. Tissue-infiltrated eosinophils in nasal polyps from patients with ECRS stained strongly with anti-SEMA4D antibody. Cell surface expression of SEMA4D on eosinophils from patients with ECRS was reduced, which was due to matrix metalloproteinase-9-mediated cleavage of membrane SEMA4D. Soluble SEMA4D induced eosinophil transendothelial migration. Treatment with anti-SEMA4D antibody ameliorated eosinophilic infiltration in sinus tissues and nasal lavage fluid in the ECRS animal model.

Conclusions: Eosinophil-derived SEMA4D aggravates ECRS. Levels of serum SEMA4D reflect disease severity, and anti-SEMA4D antibody has therapeutic potential as a treatment for ECRS.

Keywords: ECRS; SEMA4D; Semaphorin4D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antigens, CD / immunology
  • Antigens, CD / metabolism*
  • Antigens, CD / pharmacology
  • Chronic Disease
  • Eosinophilia / immunology
  • Eosinophilia / metabolism*
  • Eosinophils / drug effects
  • Eosinophils / immunology
  • Eosinophils / metabolism
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Middle Aged
  • Recombinant Proteins / pharmacology
  • Rhinitis / immunology
  • Rhinitis / metabolism*
  • Semaphorins / immunology
  • Semaphorins / metabolism*
  • Semaphorins / pharmacology
  • Sinusitis / immunology
  • Sinusitis / metabolism*
  • Transendothelial and Transepithelial Migration / drug effects


  • Antigens, CD
  • CD100 antigen
  • Recombinant Proteins
  • Semaphorins